source
- Xenon shares plunge 23% after voluntary hold on psychiatry trials, despite filing NDA for epilepsy drugXenon Pharmaceuticals announced that its lead asset azetukalner (AZK) has been submitted to the FDA as a new drug application for focal onset seizures. At the same time, the company disclosed a vo…
- Electra Therapeutics raises $350 million in Nasdaq IPO to fund commercial expansionElectra Therapeutics announced that it priced its initial public offering on the Nasdaq at $350 million, becoming the 21st biotech to go public in 2026. The Bay Area‑based company said the capital…